Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sheena Patel

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult Costa Mesa, CA Physician Assistant

NPI 1932454709 CMS profile 10963468

3151 Airway Ave Ste G1, Costa Mesa, CA 92626

Open in the dashboard

General payments

$202,068

1,264 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheena Patel of Costa Mesa, CA is reported in the CMS Open Payments database as having received $202,068 across 1,264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,287 168
2024 General $34,898 244
2023 General $72,767 299
2022 General $56,757 292
2021 General $32,357 261

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheena Patel
  • Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Sheena Patel were reported at $5,287. Among 197 Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles paid that year, the median was $174 and the middle half received between $71 and $653.

Show as a table
Year Sheena Patel Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $32,357 $152 $38–$472 $132
2022 $56,757 $172 $73–$546 $149
2023 $72,767 $156 $56–$560 $160
2024 $34,898 $158 $39–$521 $164
2025 $5,287 $174 $71–$653 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $92,277 223 payments
  2. AbbVie, Inc. $62,559 209 payments
  3. Otsuka America Pharmaceutical, Inc. $22,177 111 payments
  4. Alkermes, Inc. $5,894 43 payments
  5. Teva Pharmaceuticals USA, Inc. $2,963 147 payments
  6. ITI, Inc. $2,776 138 payments
  7. Astellas Pharma US Inc $2,010 1 payment
  8. Allergan Inc. $1,821 2 payments
  9. Neurocrine Biosciences, Inc. $1,580 65 payments
  10. Lundbeck LLC $1,282 91 payments
  11. Other $6,728 234 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $131,971 102 payments
  2. Food and Beverage $29,313 1,071 payments
  3. Travel and Lodging $28,790 74 payments
  4. Consulting Fee $11,893 11 payments
  5. Education $100 6 payments
Products named General payments · program years 2021–2025
  1. INVEGA SUSTENNA $89,094 175 payments
  2. INVEGA TRINZA $87,251 144 payments
  3. VRAYLAR $60,222 165 payments
  4. REXULTI $21,077 81 payments
  5. LYBALVI Cns $5,507 33 payments
  6. LYBALVI Cns $5,191 20 payments
  7. LYBALVI Cns $5,097 16 payments
  8. LYBALVI Cns $5,097 16 payments
  9. SPRAVATO $3,148 64 payments
  10. CAPLYTA $2,526 125 payments
  11. Other $19,514 786 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,387

Median for Physician Assistant: 241

Drug cost

$252,399

Median for Physician Assistant: $4,110

Branded share of claims

24.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 11 $92,904
Rexulti Brexpiprazole Brand 27 $40,280
Vraylar Cariprazine Hcl Brand 26 $36,826
Invega Sustenna Paliperidone Palmitate Brand 15 $35,425
Risperdal Consta Risperidone Microspheres Brand 24 $14,505
Auvelity Dextromethorphan Hbr/Bupropion Brand 12 $7,956
Trintellix Vortioxetine Hydrobromide Brand 13 $6,027
Vyvanse Lisdexamfetamine Dimesylate Brand 13 $5,147
Bupropion Xl Bupropion Hcl Brand 105 $1,620
Quetiapine Fumarate Er Quetiapine Fumarate Brand 39 $1,431

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$16,242

Medicare's payments for the services billed

Medicare patients

31

Average age 62

Services billed

253

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 74%
High blood pressure 61%
Arthritis 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$14,604 26 —
INVEGA SUSTENNA
$6,318 15 —
INVEGA TRINZA
$5,858 — —
REXULTI
$4,198 27 —
CAPLYTA
$625 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Adult in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record